Home  |  Contact

Cellosaurus KMS-12-PE (CVCL_1333)

[Text version]

Cell line name KMS-12-PE
Synonyms KMS 12 PE; KMS-12_PE; KMS-12PE; KMS12-PE; KMS12PE
Accession CVCL_1333
Resource Identification Initiative To cite this cell line use: KMS-12-PE (RRID:CVCL_1333)
Comments Part of: MD Anderson Cell Lines Project.
Population: Japanese.
Doubling time: 62 hours (PubMed=2519219).
Doubling time: ~60-80 hours (DSMZ).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Derived from sampling site: Pleural effusion.
Sequence variations Mutation; HGNC; 11998; TP53; Simple; p.Arg337Leu (c.1010G>T); ClinVar=VCV000142828; Zygosity=Homozygous (PubMed=21173094; CCLE; Cosmic-CLP).
HLA typing Source: PubMed=25688540
Class I
HLA-AA*26,33
HLA-BB*35,44
HLA-CC*03,14
Disease Plasma cell myeloma (NCIt: C3242)
Multiple myeloma (ORDO: Orphanet_29073)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_1334 ! KMS-12-BM
Sex of cell Female
Age at sampling 64Y
Category Cancer cell line
STR profile Source(s): DSMZ; JCRB; PubMed=25877200

Markers:
AmelogeninX
CSF1PO9
D3S135816
D5S81814
D7S82011,12
D8S117916
D13S3178
D16S53911
D18S5115
D21S1130.2,32.2
FGA20
Penta D14
Penta E12,18
TH016,9
TPOX8,11
vWA14,16

Run an STR similarity search on this cell line
Web pages https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
https://tcpaportal.org/mclp/
Publications

PubMed=2479409; DOI=10.1111/j.1365-2141.1989.tb00252.x
Ohtsuki T., Yawata Y., Wada H., Sugihara T., Mori M., Namba M.
Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32).
Br. J. Haematol. 73:199-204(1989)

PubMed=2519219
Ohtsuki T., Yawata Y., Namba M.
Establishment and characterization of five human myeloma cell lines.
Hum. Cell 2:297-303(1989)

PubMed=2768132; DOI=10.1007/BF02623725
Namba M., Ohtsuki T., Mori M., Togawa A., Wada H., Sugihara T., Yawata Y., Kimoto T.
Establishment of five human myeloma cell lines.
In Vitro Cell. Dev. Biol. 25:723-729(1989)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x
Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T., Aizawa Y., Ueda R., Seto M.
Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.
Jpn. J. Cancer Res. 89:712-718(1998)

DOI=10.1002/1438-826X(200005)1:1<48::AID-GNFD48>3.0.CO;2-B
Otsuki T., Yamada O., Yata K., Nakazawa N., Taniwaki M., Sakaguchi H., Yawata Y., Ueki A.
Genetic and biological characterization of human myeloma cell lines: an overview of the lines established at Kawasaki Medical School.
Gene Funct. Dis. 1:48-56(2000)

DOI=10.1007/0-306-46877-8_4
Jernberg-Wiklund H., Nilsson K.
Multiple myeloma cell lines.
(In) Human cell culture. Vol. 3. Cancer Cell Lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000)

PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2
Drexler H.G., Matsuo Y.
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Leuk. Res. 24:681-703(2000)

PubMed=11039672
Otsuki T., Hata H., Harada N., Matsuzaki H., Yata K., Wada H., Yawata Y., Ueki A., Yamada O.
Cellular biological differences between human myeloma cell lines KMS-12-PE and KMS-12-BM established from a single patient.
Int. J. Hematol. 72:216-222(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=15215163; DOI=10.1016/S0002-9440(10)63276-2
Inoue J., Otsuki T., Hirasawa A., Imoto I., Matsuo Y., Shimizu S., Taniwaki M., Inazawa J.
Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.
Am. J. Pathol. 165:71-81(2004)

PubMed=16956823
Bataille R., Jego G., Robillard N., Barille-Nion S., Harousseau J.-L., Moreau P., Amiot M., Pellat-Deceunynck C.
The phenotype of normal, reactive and malignant plasma cells Identification of 'many and multiple myelomas' and of new targets for myeloma therapy.
Haematologica 91:1234-1240(2006)

PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003
Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J., Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T., Zhu Y.-X., Fogle H., Price-Troska T., Ahmann G., Mancini C., Brents L.A., Kumar S., Greipp P., Dispenzieri A., Bryant B., Mulligan G., Bruhn L., Barrett M., Valdez R., Trent J.M., Stewart A.K., Carpten J., Bergsagel P.L.
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Cancer Cell 12:131-144(2007)

PubMed=18647998; DOI=10.1093/jncimonographs/lgn011
Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.
Characterization of MYC translocations in multiple myeloma cell lines.
J. Natl. Cancer Inst. Monogr. 39:25-31(2008)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21173094; DOI=10.3324/haematol.2010.033456
Moreaux J., Klein B., Bataille R., Descamps G., Maiga S., Hose D., Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M., Pellat-Deceunynck C.
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.
Haematologica 96:574-582(2011)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25688540; DOI=10.1002/cyto.a.22643
Maiga S., Brosseau C., Descamps G., Dousset C., Gomez-Bougie P., Chiron D., Menoret E., Kervoelen C., Vie H., Cesbron A., Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.
A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.
Cytometry A 87:285-288(2015)

CLPUB00604
Chow S.
Targeted capture and sequencing of immunoglobulin rearrangements in multiple myeloma to enable detection of minimal residual disease.
Thesis MSc (2017), University of Toronto, Canada

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30545397; DOI=10.1186/s13045-018-0679-0
Tessoulin B., Moreau-Aubry A., Descamps G., Gomez-Bougie P., Maiga S., Gaignard A., Chiron D., Menoret E., Le Gouill S., Moreau P., Amiot M., Pellat-Deceunynck C.
Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.
J. Hematol. Oncol. 11:137.1-137.13(2018)

Cross-references
Cell line collections DSMZ; ACC-606
IZSLER; BS TCL 239
JCRB; JCRB0430
Cell line databases/resources Cell_Model_Passport; SIDM01035
CGH-DB; 29-1
CGH-DB; 9140-4
LINCS_LDP; LCL-2044
Ontologies BTO; BTO:0006460
EFO; EFO_0006613
Biological sample resources BioSample; SAMN01821645
BioSample; SAMN01821692
BioSample; SAMN03472936
Chemistry resources ChEMBL-Cells; CHEMBL3308553
ChEMBL-Targets; CHEMBL2366257
PharmacoDB; KMS12PE_764_2019
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-TABM-1088
GEO; GSM99383
GEO; GSM562811
GEO; GSM827273
Other Wikidata; Q54900169
Polymorphism and mutation databases Cosmic; 753568
Cosmic; 2081426
Cosmic; 2367301
Cosmic; 2809764
IARC_TP53; 28504
Progenetix; CVCL_1333
Entry history
Entry creation04-Apr-2012
Last entry update20-May-2021
Version number34